Portfolio company
AB2 Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops Tadekinig alfa, a recombinant protein treatment for patients suffering from severe IL-18 driven systemic autoinflammatory and hyperinflammatory diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
HI-Bio
This biotechnology company develops targeted therapies for patients suffering from severe immune-mediated diseases.
Advesya
This biotech company develops immunotherapies and antibody-drug conjugates targeting IL-1RAP for patients with cancer and autoimmune diseases.
Alpine Immune
This company develops protein-based immunotherapies for patients with autoimmune and inflammatory diseases, such as IgA nephropathy and systemic lupus erythematosus.
Bright Peak Therapeutics
This biotechnology company develops engineered cytokine immunotherapies and immunoconjugates to treat patients with cancer and autoimmune diseases.
ATB Therapeutics
The company develops engineered antibody therapies for patients with cancer and autoimmune diseases using a proprietary bioengineering platform.
ABIONYX Pharma
The company develops recombinant HDL-based biotherapies for patients with sepsis, renal diseases, and ophthalmological conditions.
Abliva
This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.
Human Immunology Biosciences (HI-Bio)
This biotechnology company develops targeted immunotherapies for patients with rare, severe immune-mediated diseases, such as chronic kidney conditions and antibody-mediated transplant rejection.